Beta-cell Function, Self-rated Health, and Lifestyle Habits in 64-Year-Old Swedish Women with Metabolically Healthy Obesity Phenotype

Ola Hjelmgren¹, Anders Gummesson², Göran Bergström¹,³, Caroline Schmidt³,*

Departments of ¹Clinical Physiology and ²Clinical Genetics, Sahlgrenska University Hospital, Göteborg; ³Institution for Medicine, Department of Molecular and Clinical Medicine, Sahlgrenska Academy at Gothenburg University, Göteborg, Sweden

*Corresponding author: Caroline Schmidt

https://orcid.org/0000-0001-8534-3237

Wallenberg Laboratory for Cardiovascular Research, Sahlgrenska University Hospital, 413 45 Göteborg, Sweden

Tel: +46-31-342-9696, E-mail: caroline.schmidt@wlab.gu.se

Running title: Beta-cell Function in Metabolically Healthy Obesity

Received 2019-12-17; Revised 2020-02-08; Accepted 2020-02-29
Background: A subset of obese individuals do not present metabolic abnormalities that commonly define the metabolic syndrome (MetS). This is referred to as a metabolically healthy obese (MHO) phenotype. The aim of the present study was to evaluate the prevalence of the MHO phenotype and its relationship with beta cell dysfunction by measuring C-peptide and proinsulin, anthropometric-, metabolic- and lipid appearance, as well as lifestyle behaviors and self-rated health in a cohort of 64-year-old Swedish women.

Methods: The National Cholesterol Education Program definition was used to assess MetS. We defined normal weight as BMI 18.5–24.9 kg/m² and obesity as BMI ≥30 kg/m² to categorize participants as metabolically healthy normal weight, normal weight obese, and MHO.

Results: The MHO phenotype represented 36.3% of obese participants and 16.3% of total participants in the analytic sample. The MHO group were at greater risk of having proinsulin levels >11 pmol/L, indicating impaired beta cell function. Further, homeostatic model assessment for insulin resistance, fasting plasma levels of insulin, and C-peptide showed significant trends, with the MHO phenotype group having intermediate levels. Individuals with the MHO phenotype exhibited lifestyle behaviors such as leisure time physical activity and alcohol intake measures that were intermediate.

Conclusion: In this study, we demonstrate that over a third of the obese women in our sample were MHO. Further, women with the MHO phenotype showed intermediate profiles considering beta cell function and insulin resistance, as well as metabolic variables, and tended to rate their general health as worse than otherwise similar individuals of normal weight.

Key words: Metabolically benign obesity, Beta cell
INTRODUCTION

Obesity is a complex, heterogeneous condition with significant phenotypic variation.1 Whereas obesity is closely related to clustering of metabolic risk factors and increased morbidity and mortality, a subset of obese individuals do not present with metabolic abnormalities. This phenotype is considered metabolically healthy obese (MHO).2,3 Why these individuals do not develop metabolic syndrome (MetS) is currently unknown.4 However, lifestyle behaviors, such as physical activity and sedentary time, may differ between MHO and metabolically unhealthy obese (MUO) phenotypes.1 Previous studies have shown inconsistent results comparing physical activity levels between MHO and MUO subjects, with some studies reporting significant differences while other studies do not.1 Further, self-rated health (SRH), an inclusive measure of health, has previously been shown to be associated with increased risk of progression to an unhealthy metabolic status in metabolically healthy individuals.5 Previous studies have also shown that low SRH is associated with increased incidence of both insulin resistance and type 2 diabetes mellitus.6,7 However, preserved insulin sensitivity and paucity of the components of the MetS may characterize the MHO phenotype. Physiologically, virtually all proinsulin molecules are cleaved into insulin and C-peptide. In healthy subjects, only a minor percentage of un-cleaved intact proinsulin is released into the circulation. However, insulin resistance leads to an increased demand for insulin, and thus the cleavage capacity of the processing enzymes may be exhausted, and proinsulin and C-peptide may be increased.9 Further, insulin resistance may cause metabolic modifications that lead to imbalance in glucose metabolism, causing chronic hyperglycemia, which in turn initiates oxidative stress and inflammatory response that leads to cell damage.10 Insulin resistance can also change systemic lipid metabolism, which leads to the development of dyslipidemia and the well-known pattern of high levels of plasma triglycerides, low levels of high-density lipoprotein, and appearance of small dense low-density lipoprotein.10 Therefore, measurements of intact proinsulin are important indirect predictors for insulin resistance and play roles as direct biomarkers of beta cell dysfunction.9
The aim of the present study was to evaluate the prevalence of the MHO phenotype and its relationships with anthropometric-, metabolic- and lipid appearance, as well as lifestyle behaviors and SRH, in a cohort of 64-year-old Swedish women. A further aim was to explore beta cell dysfunction by measuring C-peptide and proinsulin in the MHO phenotype.

METHODS

Study population and design

All participants received both written and oral information before they gave consent to take part in the study. The Ethics Committee at Sahlgrenska University Hospital approved the protocol (Dnr: S 286-01). The study population and study design have previously been extensively described elsewhere. In brief, all 64-year-old women (n=4,856) identified through the County Register in Gothenburg, Sweden, were sent an invitation letter to participate in a screening examination. Those who accepted (n=2,893) completed a brief questionnaire that was enclosed with the letter. Exclusion criteria were cancer (unless no relapse during the last 5 years), chronic inflammatory disease, severe mental disorder, other severe illness, drug addiction, or inability to understand Swedish (n=298).

Participants were invited to a screening examination including an OGTT. The OGTT procedure has previously been thoroughly described. The World Health Organization (WHO) criteria for capillary blood glucose values for cutoff were used. No OGTTs were performed on subjects with known diabetes. The examinations included a questionnaire soliciting information regarding previous diseases, current medication, smoking habits, heredity for diabetes, TV time, leisure time physical activity (LTPA) and SRH. Anthropometric measurements were performed, and blood pressure and heart rate were recorded. Body weight was measured in light clothing. Waist and hip circumferences were measured according to current guidelines. Finally, 639 women were included in the study.
Definition of the phenotype groups

The National Cholesterol Education Program definition was used to assess MetS (Supplementary Table 1). By defining normal weight as BMI 18.5–24.9 kg/m² and obesity as BMI ≥30 kg/m², the participants were categorized as (1) metabolically healthy normal weight (MHNW; n=180), (2) metabolically healthy obese (MHO; n=53), and (3) metabolically unhealthy obese (MUO; n=93) (Supplementary Table 2). This resulted in a sample of 326 women. The remaining 313 women were categorized as metabolic abnormal, normal weight, metabolic healthy, overweight, or metabolic abnormal, overweight.

Biochemical analysis

The biochemical analyses we performed have been described in detail elsewhere. All analyses were performed at the Wallenberg Laboratory for Cardiovascular Research, Sahlgrenska University Hospital, Gothenburg, Sweden.

Assessment of SRH

SRH was assessed by the question “In general, how would you rate your health?” Answers were dichotomized into two groups, good health (excellent and good) and average health or less (average, poor and very poor) based on previous studies. SRH was further assessed by the question “In general, how would you rate your health compared to others your age?” with answers divided into three categories, better (much better and better), neither better nor worse, and worse (worse and much worse).

Statistics

The IBM SPSS version 22.0 (IBM Corp., Armonk, NY, USA) was used for all statistical analyses. Normally distributed continuous data are presented as the mean±standard deviation (SD). Skewed data are presented as the median and range and nominal data are presented as number and percent.
Comparisons between groups were analyzed by one-way analysis of variance with the least significant difference post-hoc test. In addition, one-way test was used for analyzing trends between groups. Trend analyses in nonparametric variables were performed with Jonckheere-Terpstra test. Analyses of nominal data were performed with chi-square tests. The \( P \)-values <0.05 were considered statistically significant.

**RESULTS**

In the sample of 326 women, 71.5% were metabolically healthy and 44.8% were obese. The MHO phenotype represented 36.3% of obese participants and 16.3% of participants in the total sample. The mean age was 64.5 years (SD, 0.3). Values for baseline anthropometrics and lifestyle behaviors, baseline metabolic factors, including insulin variables, and lipids are presented in Tables 1 and 2, respectively. Briefly, the majority of the variables showed significant trends, with the MHO phenotype group having intermediate levels and the MUO phenotype group having levels that were the most unfavorable. The MHO group had significantly increased BMI, weight, waist circumference, and blood pressure, compared to the MHNW group. Further, fasting plasma insulin levels, plasma pro-insulin, C-peptide, triglycerides, apolipoprotein B levels, and apolipoprotein B to A-I ratio were significantly increased, while high-density lipoprotein-cholesterol was significantly lower in the MHO group than in the MHNW group. However, total cholesterol did not differ between the phenotype groups, nor did low-density lipoprotein-cholesterol.

Fasting plasma levels of insulin, proinsulin, and C-peptide showed significant trends with the MHO phenotype group having intermediate levels and the MUO phenotype group having the highest levels. Proinsulin levels \( >11 \) pmol/L indicating beta-cell dysfunction, was most common in the MUO group (30%). In the MHO group, the corresponding figure was 9.8%, while only one patient (0.6%) in the MHNW group had proinsulin levels above 11 pmol/L. The risk ratio was 18.2 (95% confidence interval, 2.1 to 159.3) for increased risk among MHO subjects to have a proinsulin level \( >11 \) pmol/L compared
to MHNW subjects. Insulin resistance assessed as homeostatic model assessment for insulin resistance (HOMA-IR) significantly differed between the MHO and the MHNW groups. Further, the MUO group had significantly higher values of HOMA-IR compared to both other groups.

Both obese phenotype groups were more likely to have lost $\geq 5$ kg in weight on purpose in less than one year compared to the normal weight group. LTPA showed a significant trend towards less activity in the MUO group, with the MHNW group reporting the most activity. However, no difference was observed in the number of subjects performing LTPA at least 30 minutes 1–2 times per week while breaking sweat between the MHO and the MHNW groups, but this variable differed significantly between the MUO and MHNW groups. No difference between phenotype groups was observed for TV time $\geq 3–6$ hours per day. The MUO group reported significantly more cigarette years, representing smoking habits, compared to the normal weight group.

SRH showed a significant trend with the MHO as the intermediate group and the MUO group having the most subjects who rated their general health as average. A similar trend was observed for rating health worse than that of others their own age. A significant difference was observed between the MHO group and the MHNW group, with more subjects rating their general health as average among those with MHO. No difference was observed between the MHO and the MHNW groups in rating their health to be worse than others their own age, while a greater number of individuals in the MUO group rated their health worse than others their own age when compared to the MHNW and MHO groups (Figs. 1 and 2).

**DISCUSSION**

The results from this sample of 64-year-old women showed that one-third of the obese participants were of MHO phenotype. Compared with the prevalence of MHO in cohorts comprising The Healthy Obese Project sample, the prevalence reported in the present study is higher. One previous study found
that the prevalence of MHO ranges between 12% and nearly 60% in women, depending on the definition used. However, the criteria used for the definitions of MHO in that study did not include exactly the same criteria used in the present study.

An interesting observation in this study is that the MHO group rated their health as similar to others their own age, like the MHNW group, while a significant difference in general health was observed between these groups. Previously, SRH was suggested to be an independent risk factor of metabolic abnormalities, and studies have shown that SRH is low in people with MetS and obesity. An earlier study of 40-year-old Finnish males showed that those with BMI $\geq 30$ kg/m$^2$ rated their health worse than men who were of normal weight. This finding is in line with that of the present study in a sample of women. Further, the MUO group reported significantly worse results for SRH compared to the other phenotype groups. A recent study showed low SRH to be independently associated with the risk of progression to metabolically unhealthy status in metabolically healthy individuals, especially in those with obesity.

Physical activity is known to be associated with health-related benefits leading to, for instance, lower risk of obesity and diabetes. In the present study, the proportion of subjects performing LTPA for at least 30 minutes $\geq 1$–$2$ times per week while breaking sweat was similar across phenotype groups, nor were there differences between obese groups. A previous study revealed no difference between MHO subjects and non-MHO subjects in terms of moderate-to-vigorous activity in a group of 45- to 85-year-old individuals. Further, another previous study showed that MHO subjects spent more time stepping/day and less time being sedentary compared to MUO subjects, while there was no difference in sedentary time/day or total stepping time/day between MHO and MHNW subjects. Previous studies utilized TV viewing time as a proxy measure to assess sedentary behavior in MHO and MUO individuals. In the present study, we found no difference in TV time, consistent with previous studies. The lack of difference in physical activity and TV time between the obese phenotype groups may be due to the small groups included in our study.
MHO individuals may have higher inflammatory markers when compared with metabolically healthy non-obese subjects, and it is suggested that this intermediate inflammatory status put them at delayed risk of metabolic disorders. In our study, differences in both waist circumference and C-reactive protein were observed between MHO and MHNW subjects, while only waist circumference differed between the MHO and MUO phenotypes.

Proinsulin is the precursor form of insulin, and is synthesized, processed, and cleaved to form mature insulin and C-peptide. Glucose intolerant and/or insulin resistant individuals have increased concentrations of proinsulin. In the present study, MHO participants had increased levels of plasma proinsulin, split proinsulin, and C-peptide compared to MHNW participants, but decreased values compared to MUO participants. Plasma proinsulin levels >11 pmol/L were increased and considered indicative of beta cell dysfunction in a previous study. In the present study, MHO participants had a significantly increased plasma proinsulin value of 5.9 pmol/L compared to MHNW participants, who had an average of 3.1 pmol/L, while MUO participants showed a significantly increased value of 11.5 pmol/L. In addition, proinsulin values >11 pmol/L were significantly less common in the MHO group compared to the MUO group. This suggests that the MHO participants in our study are in earlier phases of metabolic disease, while the MUO participants had already developed beta cell dysfunction.

Previously, C-peptide was shown to be associated with decreased levels of high-density lipoprotein. We observed that C-peptide levels were highest in the MUO group, that the MHNW group had the lowest levels, and the MHO group showed intermediate levels, while high-density lipoprotein-cholesterol showed an inverse trend with the lowest level in the MUO group. A similar pattern was observed by our research group in a cohort of initially healthy 58-year-old men (not published). Further, in the present study showed the MHO subjects were more insulin sensitive than the MUO subjects, a finding that agrees with those of previous studies.

Insulin resistance assessed by HOMA-IR previously indicated that worse metabolic conditions are associated with higher risk of increased HOMA index. This is in line with the findings of the present
study, in which there was a trend toward increased HOMA index with worsening metabolic condition, with the MUO group having the highest levels and the MHO group having intermediate values. Compared to the MHNW group, both obese groups had significantly increased HOMA values, which also agrees with the results of previous studies.\textsuperscript{31}

There are limitations as well as strengths of the present study that need to be considered. Women of the same age with different degrees of insulin sensitivity and obesity were included in our sample, and those with prevalent cardiovascular disease and those who had received cardiovascular disease medication were excluded. This approach has the disadvantage that the cohort is less representative of the general population, and it may have affected the number of MUO participants we included. Therefore, we may have overestimated the prevalence of MHO in the obese population. On the other hand, the participants were selected in a structured way among a representative, homogenous population sample, and confounding factors such as age, sex, and concomitant cardiovascular disease were constant at baseline. To define obesity using BMI is another limitation because it does not differentiate between body lean mass and body fat mass, and a person can have a high BMI but still have a very low fat mass.\textsuperscript{32} Waist circumference has been shown to be a more specific measure of visceral obesity.\textsuperscript{33} Further, results from the Framingham study showed that being underweight is associated with increased risk of non-cardiovascular mortality.\textsuperscript{24} In our study, we included normal weight participants with BMI 18.5–24.9 kg/m\textsuperscript{2}, as previously suggested by WHO,\textsuperscript{34} with the intention of excluding underweight participants and avoiding underestimating body weight in the normal weight group.

In conclusion, this cross-sectional study detected an MHO prevalence of nearly 40% among a homogeneous sample of obese 64-year-old women, and found that women with MHO phenotype have an intermediate profile for variables measuring beta cell function and HOMA index, as well as for anthropometric and metabolic variables. Further, women in the MHO group rated their general health as worse compared to those with normal weight. This emphasizes the question of whether MHO individuals, defined by having few MetS features, actually are healthy.
CONFLICTS OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGMENTS

Grants from the Swedish Heart-Lung Foundation, the Swedish Medical Research Council (12270 and 10880), and AstraZeneca, Mölndal, Sweden, supported this work.

The authors would like to thank the staff of the Cardiometabolic Clinical research group at the Wallenberg Laboratory for Cardiovascular Research for technical assistance: Marie Louise Ekholm, Carita Fagerlund, Magdalena Göthberg, Birgitta Jannemark, Marie Jonsson, Pia Lindén, and Ulrica Prahl Gullberg.

AUTHOR CONTRIBUTION

Study concept and design: GB; acquisition of data: GB; analysis and interpretation of data: CS; drafting of the manuscript: CS and AG; critical revision of the manuscript: GB and OH; statistical analysis: CS; obtained funding: GB; administrative, technical, or material support: CS; and study supervision: GB.
**REFERENCES**

1. Camhi SM, Crouter SE, Hayman LL, Must A, Lichtenstein AH. Lifestyle Behaviors in metabolically healthy and unhealthy overweight and obese women: a preliminary study. PLoS One 2015;10:e0138548.

2. Truthmann J, Mensink GB, Bosy-Westphal A, Scheidt-Nave C, Schienkiewitz A. Metabolic health in relation to body size: changes in prevalence over time between 1997-99 and 2008-11 in Germany. PLoS One 2016;11:e0167159.

3. Goday A, Calvo E, Vázquez LA, Caveda E, Margallo T, Catalina-Romero C, et al. Prevalence and clinical characteristics of metabolically healthy obese individuals and other obese/non-obese metabolic phenotypes in a working population: results from the Icaria study. BMC Public Health 2016;16:248.

4. Korhonen PE, Korsoff P, Vahlberg T, Kaaja R. Lifestyle of metabolically healthy obese individuals. Prim Care Diabetes 2015;9:179-83.

5. Kim MH, Chang Y, Jung HS, Shin H, Ryu S. Impact of self-rated health on progression to a metabolically unhealthy phenotype in metabolically healthy obese and non-obese individuals. J Clin Med 2019;8:E34.

6. Andersson S, Ekman I, Fröberg F, Daka B, Lindblad U, Larsson CA. The association between self-rated health and impaired glucose tolerance in Swedish adults: a cross-sectional study. Scand J Prim Health Care 2013;31:111-8.

7. Tapp RJ, O'Neil A, Shaw JE, Zimmet PZ, Oldenburg BF; AusDiab Study Group. Is there a link between components of health-related functioning and incident impaired glucose metabolism and type 2 diabetes? The Australian Diabetes Obesity and Lifestyle (AusDiab) study. Diabetes Care 2010;33:757-62.

8. Owei I, Umekwe N, Provo C, Wan J, Dagogo-Jack S. Insulin-sensitive and insulin-resistant obese and non-obese phenotypes: role in prediction of incident pre-diabetes in a longitudinal biracial cohort. BMJ Open Diabetes Res Care 2017;5:e000415.
9. Pfützner A, Forst T. Elevated intact proinsulin levels are indicative of Beta-cell dysfunction, insulin resistance, and cardiovascular risk: impact of the antidiabetic agent pioglitazone. J Diabetes Sci Technol 2011;5:784-93.

10. Ormazabal V, Nair S, Elfeky O, Aguayo C, Salomon C, Zuñiga FA. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol 2018;17:122.

11. Brohall G, Behre CJ, Hulthe J, Wikstrand J, Fagerberg B. Prevalence of diabetes and impaired glucose tolerance in 64-year-old Swedish women: experiences of using repeated oral glucose tolerance tests. Diabetes Care 2006;29:363-7.

12. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: report of WHO consultation. Part 1: diagnosis and classification of diabetes mellitus. Geneva: World Health Organization; 1999.

13. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.

14. Malik S, Wong ND, Franklin SS, Kamath TV, L'Italien GJ, Pio JR, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004;110:1245-50.

15. Englund Ogge L, Brohall G, Behre CJ, Schmidt C, Fagerberg B. Alcohol consumption in relation to metabolic regulation, inflammation, and adiponectin in 64-year-old Caucasian women: a population-based study with a focus on impaired glucose regulation. Diabetes Care 2006;29:908-13.

16. Schmidt C, Fagerberg B. ApoB/apoA-I ratio is related to femoral artery plaques in 64-year-old women also in cases with low LDL cholesterol. Atherosclerosis 2008;196:817-22.
17. Kivimäki M, Head J, Ferrie JE, Hemingway H, Shipley MJ, Vahtera J, et al. Working while ill as a risk factor for serious coronary events: the Whitehall II study. Am J Public Health 2005;95:98-102.

18. Näslindh-Ylispangar A, Sihvonen M, Vanhanen H, Kekki P. Self-rated health and risk factors for metabolic syndrome among middle-aged men. Public Health Nurs 2005;22:515-22.

19. van Vliet-Ostaptchouk JV, Nuotio ML, Slagter SN, Doiron D, Fischer K, Foco L, et al. The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large cohort studies. BMC Endocr Disord 2014;14:9.

20. Velho S, Paccaud F, Waerber G, Vollenweider P, Marques-Vidal P. Metabolically healthy obesity: different prevalences using different criteria. Eur J Clin Nutr 2010;64:1043-51.

21. Ekelund U, Besson H, Luan J, May AM, Sharp SJ, Brage S, et al. Physical activity and gain in abdominal adiposity and body weight: prospective cohort study in 288,498 men and women. Am J Clin Nutr 2011;93:826-35.

22. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Härmäläinen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50.

23. de Winter M, Rioux BV, Boudreau JG, Bouchard DR, Sénéchal M. Physical activity and sedentary patterns among metabolically healthy individuals living with obesity. J Diabetes Res 2018;2018:7496768.

24. de Rooij BH, van der Berg JD, van der Kallen CJ, Schram MT, Savelberg HH, Schaper NC, et al. Physical activity and sedentary behavior in metabolically healthy versus unhealthy obese and non-obese individuals: the Maastricht study. PLoS One 2016;11:e0154358.
25. Hankinson AL, Daviglus ML, Van Horn L, Chan Q, Brown I, Holmes E, et al. Diet composition and activity level of at risk and metabolically healthy obese American adults. Obesity (Silver Spring) 2013;21:637-43.

26. Bell JA, Kivimäki M, Batty GD, Hamer M. Metabolically healthy obesity: what is the role of sedentary behaviour? Prev Med 2014;62:35-7.

27. Wildman RP, Kaplan R, Manson JE, Rajkovic A, Connelly SA, Mackey RH, et al. Body size phenotypes and inflammation in the Women’s Health Initiative Observational Study. Obesity (Silver Spring) 2011;19:1482-91.

28. Vangipurapu J, Stančáková A, Kuulasmaa T, Kuusisto J, Laakso M. Both fasting and glucose-stimulated proinsulin levels predict hyperglycemia and incident type 2 diabetes: a population-based study of 9,396 Finnish men. PLoS One 2015;10:e0124028.

29. Banu S, Jabir NR, Manjunath CN, Shakil S, Kamal MA. C-peptide and its correlation to parameters of insulin resistance in the metabolic syndrome. CNS Neurol Disord Drug Targets 2011;10:921-7.

30. Dhana K, Koolhaas CM, van Rossum EF, Ikram MA, Hofman A, Kavousi M, et al. Metabolically healthy obesity and the risk of cardiovascular disease in the elderly population. PLoS One 2016;11:e0154273.

31. Iglesias Molli AE, Penas Steinhardt A, López AP, González CD, Vilariño J, Frechtel GD, et al. Metabolically healthy obese individuals present similar chronic inflammation level but less insulin-resistance than obese individuals with metabolic syndrome. PLoS One 2017;12:e0190528.

32. Nuttall FQ. Body Mass Index: Obesity, BMI, and health: a critical review. Nutr Today 2015;50:117-28.

33. Bhurosy T, Jeewon R. Pitfalls of using body mass index (BMI) in assessment of obesity risk. Curr Res Nutr Food Sci 2013;1:71-6.
34. Pencina M, D'Agostino RB, Fox CS, Vasan RS, Kannel WB. Obesity is independently associated with long-term risk of cardiovascular mortality and underweight with risk of non-cardiovascular mortality in Framingham offspring cohort [abstract]. Circulation 2009;120:S508.
Table 1. Baseline anthropometric values and life style behaviors of the study participants according to phenotype

| Variable                                      | Metabolically healthy normal weight (n=180) | Metabolically healthy obese (n=53) | Metabolically unhealthy obese (n=93) | P for trend |
|-----------------------------------------------|-------------------------------------------|-----------------------------------|-------------------------------------|-------------|
| BMI (kg/m²)                                   | 22.9±1.5                                  | 33.2±3.2§                         | 34.3±3.4‖                         | <0.001      |
| Weight (kg)                                   | 61.8±5.8                                  | 89.3±10.1‡                        | 91.2±10.3‡                        | <0.001      |
| Waist circumference (cm)                      | 81±5                                      | 104±8§                            | 109±10§                           | <0.001      |
| Systolic blood pressure (mmHg)                | 135±19                                    | 138±18†                           | 147±17§                           | <0.001      |
| Diastolic blood pressure (mmHg)               | 75±6                                      | 78±9                              | 83±8‖                             | <0.001      |
| LTPA at least 30 minutes 1–2 times/wk breaking sweat | 75 (41.7)                                | 21 (39.6)                         | 27 (29.0)                         | 0.005       |
| I have on purpose and on occasion lost ≥5 kg in weight in less than 1 year | 70 (38.9)                                | 41 (77.4)§                        | 79 (84.9)§                        | <0.001      |
| TV time ≥3–6 hours/day                        | 25 (13.9)                                 | 7 (13.2)                          | 22 (23.7)                         | 0.173       |
| Smoking–cigarette years*                     | 14.3 (74.9)                               | 22.5 (55.7)                       | 21.6 (91.6)                       | 0.021       |
| Alcohol intake/day (g)a                      | 8.9 (36.3)                                | 5.0 (46.3)                        | 2.7 (38.2)                        | 0.006       |
| Lipid medication                              | 15 (8.3)                                  | 4 (7.5)                           | 24 (25.8)                         | <0.001      |
| Hypertensive medication                      | 34 (18.9)                                 | 17 (32.1)                         | 54 (53.8)                         | <0.001      |

Values are presented as mean±standard deviation or number (%).
*Median (range); †P<0.05 vs. metabolically healthy normal weight; ‡P<0.01 vs. metabolically healthy normal weight; §P<0.001 vs. metabolically healthy normal weight; ¶P<0.05 vs. metabolically healthy and obese; §P<0.01 vs. metabolically healthy and obese; ¶P<0.001 vs. metabolically healthy obese.

BMI, body mass index; LTPA, leisure time physical activity.
Table 2. Baseline metabolic and insulin factors for the study participants according to phenotype

| Variable                          | Metabolically healthy normal weight (n=180) | Metabolically healthy obese (n=53) | Metabolically unhealthy obese (n=93) | P for trend |
|----------------------------------|-------------------------------------------|-----------------------------------|-------------------------------------|-------------|
| Fasting plasma glucose (mmol/L)  | 5.3±1.8                                   | 5.1±1.04                          | 6.9±2.5‡,**                         | <0.001      |
| Fasting plasma insulin (pmol/L)  | 40.5±47.1                                 | 61.9±35.4§                        | 114.2±91.4§,**                      | <0.001      |
| Plasma pro-insulin (pmol/L)      | 3.1±2.0                                   | 5.9±4.8§                          | 11.5±12.4§                         | <0.001      |
| C-peptide (ng/mL)                | 522±201                                   | 779±303§                          | 1,099±496§,**                       | <0.001      |
| Insulin resistance (HOMA-IR)     | 1.61±3.26                                 | 2.10±1.37§                        | 5.75±3.39§,**                      | <0.001      |
| Total cholesterol (mmol/L)       | 5.90±1.09                                 | 5.97±0.84                         | 5.71±1.16                           | 0.215       |
| LDL-cholesterol (mmol/L)         | 3.53±0.98                                 | 3.76±0.86                         | 3.46±0.99                           | 0.729       |
| HDL-cholesterol (mmol/L)         | 1.84±0.41                                 | 1.62±0.37§                        | 1.27±0.30§,**                      | <0.001      |
| Triglycerides (mmol/L)a          | 1.08 (2.53)                               | 1.27 (1.96)§                      | 1.97 (5.15)‡,**                     | <0.001      |
| apoB (mmol/L)                    | 1.07±0.25                                 | 1.14±0.20§                        | 1.25±0.31§,**                      | <0.001      |
| apoA-I (mmol/L)                  | 1.64±0.27                                 | 1.60±0.28                         | 1.44±0.22§,**                      | <0.001      |
| apoB/apoA-I ratio               | 0.66±0.17                                 | 0.73±0.19§                        | 0.88±0.22§,**                      | <0.001      |
| Ox-LDL (U/L)                     | 56.0±18.2                                 | 58.7±16.1                         | 60.4±16.6‡                         | 0.041       |
| hsCRP (mg/L)                     | 0.79 (75.6)                               | 2.33 (20.0)§                      | 3.14 (41.2)§                      | <0.001      |

Values are presented as mean±standard deviation or number (%).

*Median (range); †P<0.05 vs. metabolically healthy normal weight; ‡P<0.01 vs. metabolically healthy normal weight; §P<0.001 vs. metabolically healthy normal weight; ¶P<0.05 vs. metabolically healthy obese; ††P<0.01 vs. metabolically healthy obese; ‡‡P<0.001 vs. metabolically healthy obese.

HOMA-IR, homeostatic model assessment for insulin resistance; LDL, low-density lipoprotein; HDL, high-density lipoprotein; apoB, apolipoprotein B; apoA-I, apolipoprotein A-I; ox-LDL, oxidized low-density lipoprotein; hsCRP, high-sensitive C-reaction protein.
Journal of Obesity & Metabolic Syndrome

This is a PDF file of an article accepted, but it is not yet the definitive version of record.

**Figure 1.** Proportion of each phenotype group rating their health as average or worse. MHNW, metabolically healthy normal weight; MHO, metabolically healthy obese; MUO, metabolically unhealthy obese.
**Figure 2.** Proportion of each phenotype group rating their health as worse compared to others their own age. MHNW, metabolically healthy, normal weight; MHO, metabolically healthy obese; MUO, metabolically unhealthy obese.
**Supplementary Table 1.** Diagnostic criteria for the metabolic syndrome according to the NCEP-ATP III

| Any combination of three or more of the following criteria |
|----------------------------------------------------------|
| • Fasting plasma glucose $\geq$ 6.1 mmol/L ($\geq$ 100 mg/dL) |
| • Blood pressure $\geq$ 130/85 mmHg (either value) or treatment |
| • Plasma triglycerides $\geq$ 1.7 mm/L ($\geq$ 150 mg/dL) |
| • Plasma HDL-cholesterol $<$ 1.0 mmol/L ($<$ 40 mg/dL) |
| • Abdominal obesity-waist girth $>$ 88 cm |

NCEP-ATP III, National Cholesterol Education Program Adult Treatment Panel III; HDL, high-density lipoprotein.
**Supplementary Table 2. Phenotype groups**

| Metabolically healthy normal weight (n=180) | Metabolically healthy obese (n=53) | Metabolically unhealthy obese (n=93) |
|-------------------------------------------|-----------------------------------|-------------------------------------|
| BMI 18.5–24.9 kg/m² | BMI ≥30 kg/m² | BMI ≥30 kg/m² |
| ≤2 MetS according to NCEP-ATP III | ≤2 MetS according to NCEP-ATP III | Fulfilled MetS according to NCEP-ATP III |

BMI, body mass index; MetS, metabolic syndrome; NCEP-ATP III, National Cholesterol Education Program Adult Treatment Panel III.
Supplementary Figure 1. Composition of the analytic cohort. MHNW, metabolically healthy, normal weight; MHO, metabolically healthy obese; MUO, metabolically unhealthy obese.